



Adding Smiles To Life

To,
National Stock Exchange of India Ltd.
Exchange Plaza, C 1, Block G,
Bandra - Kurla Complex,
Bandra (E),
Mumbai – 400 051.

Company Symbol: QMSMEDI

ISIN: INEOFMW01018

Sub: Press Release – Audited Financial Results of the Company for the half yearly and year ended March 31, 2024

Pursuant to Regulation 30 of the SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, enclosed herewith the copy of the Press Release with regard to the Audited Financial Results of the Company for the half yearly and year ended March, 31 2024.

A copy of the press release is also uploaded on the Company's website.

Kindly take the same on your records and oblige.

Thanking you,

Yours truly,

FOR QMS MEDICAL ALLIED SERVICES LIMITED

**TORAL BHADRA
COMPANY SECRETARY AND COMPLIANCE OFFICER
MEMBERSHIP NO.: A56927
DATE: MAY 24, 2024
PLACE: MUMBAI**

QMS Medical Allied Services Ltd.

📍 1A-1B / 2A-2B, Navkala Bharati Building, Plot No. 16, Prabhat Colony, Road No. 3, Santacruz (East), Mumbai - 400 055.

☎ +91-022 - 6288 1111 🌐 www.qmsmas.com

CIN: U33309MH2017PLC299748; Email Id: mm@qmsmas.com



QMS Medical Allied Services FY24 PAT up by 41%

Mumbai – May 24, 2024: QMS Medical Allied Services Limited (NSE: QMSMEDI), engaged in the marketing and distribution of a wide range of medical products, as well as prioritizing Patient Services Programs, has announced its Audited Financial Results for FY24 & Q4 FY24.

Key Financial Highlights

Particulars (₹ Cr)	FY24	FY23	YoY Change
Total Income	122.58	104.78	↑ 16.99%
EBITDA	18.80	12.07	↑ 55.83%
EBITDA (%)	15.34%	11.51%	↑ 382 BPS
PAT	9.00	6.38	↑ 41.14%
PAT (%)	7.34%	6.09%	↑ 126 BPS
EPS (₹)	5.04	3.90	↑ 29.23%

Key Highlights For FY24

- The Company announced Final Dividend of ₹ 0.5 (5%) per share against the face value of ₹ 10 per share.
- The company reported operating cash flow of ₹ 1.36 Cr for FY24 an Vs ₹ (-7.54) Cr in FY23.

Commenting on the performance, Mr. Mahesh Makhija, Chairman and Managing Director, mentioned, “I am pleased to highlight the commendable growth trajectory of QMS Medical Allied Services Limited during the reported period. Our significant increase in financial performance has been driven by a surge in our patient service programs, efforts to widen healthcare access, and our commitment to advancing nationwide well-being.

Our recent acquisition of Saarthi Healthcare Private Limited will play a crucial role in our future & will enable us to provide a highly comprehensive portfolio of services further solidifying our industry position.

We are strategically expanding our healthcare services and reach, positioning ourselves to leverage opportunities within India's burgeoning pharma and healthcare industry. Our commitment to innovation, patient outcomes, and sustainability will drive our continued success.”

Key Highlights For Q4 FY24

Conducted Patient Service Programs	<ul style="list-style-type: none">• Conducted over 25,000 patient service programs in FY23-FY24.• Benefitted 2 lakh individuals nationwide with advanced diagnostics and lifestyle management consultations.
---	---

<p>Saarathi Healthcare Acquisition</p>	<ul style="list-style-type: none"> Expands into patient services vertical by acquiring 51% stake in Saarathi Healthcare Private Limited.
---	---

About QMS Medical Allied Services Limited

Incorporated in 2017, QMS Medical Allied Services Limited is a leading medical and healthcare entity in India, specializing in the marketing and distribution of essential devices and accessories. With a focus on quality and affordability, the company offers a wide range of devices through its partnership with brands like 3M & Heine, & also its own "Q-Devices" brand. These products include glucometers, pulse oximeters, orthopaedic aids, mesh nebulizers and many more. Its extensive distribution network ensures broad accessibility, while strategic marketing efforts bolster brand recognition and expansion.

QMS MAS emerges as a prominent healthcare services provider in India, deeply committed to advancing preventive healthcare. A significant aspect is its second vertical, offering Patient Service Programs to the public. These programs provide consumers unprecedented access to specialized screening tests across the country. They serve as a driver to of preventative healthcare amongst all Indians and will eventually drive down the healthcare costs arising due to chronic disease medication and hospitalization.

In FY24, the Company has reported Total Revenue of ₹ 122.58 Cr with EBITDA of ₹ 18.80 Cr & Net Profit of ₹ 9.00 Cr.

Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Further Information Please Contact Corporate Communication Advisor

	<p>Kirin Advisors Private Limited Sunil Mudgal – Director sunil@kirinadvisors.com +91 98692 75849 www.kirinadvisors.com</p>
---	--